Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 10 of 10 results for eltrombopag

  1. Eltrombopag for treating chronic immune thrombocytopenia (TA293)

    Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune thrombocytopenia in adults.

    Technology appraisal guidance
    Last updated
    26 October 2018
    View recommendations

    Sections for TA293

  2. Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) (TA382)

    NICE is unable to make a recommendation about the use in the NHS of Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive…

    Technology appraisal guidance
    Published
    27 January 2016

    Sections for TA382

  3. Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)

    Evidence-based recommendations on avatrombopag (Doptelet) for treating primary chronic immune thrombocytopenia in adults.

    Technology appraisal guidance
    Published
    15 December 2022
    View recommendations

    Sections for TA853

  4. Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)

    Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making

    Evidence summary
    Published
    21 October 2014

  5. NICE recommends that research should be carried out to directly compare eltrombopag with non-thrombopoietin receptor agonist treatments routinely used in UK clinical practice.

    NICE recommends that research should be carried out to directly compare eltrombopag with non-thrombopoietin receptor agonist treatments...

    Research recommendation
    Published
    9 June 2015

  6. NICE recommends research generating and analysing observational data including, but not limited to, the existing UK ITP Registry, which collects data on the long-term outcomes of patients treated with eltrombopag and romiplostim.

    which collects data on the long-term outcomes of patients treated with eltrombopag and romiplostim. Any explanatory notes(if applicable)...

    Research recommendation
    Published
    9 June 2015

  7. Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)

    Evidence-based recommendations on fostamatinib (Tavlesse) for chronic refractory chronic immune thrombocytopenia in adults.

    Technology appraisal guidance
    Published
    19 October 2022
    View recommendations

    Sections for TA835

  8. Eltrombopag for untreated severe aplastic anaemia [ID1198]

    Discontinued [GID-TA10284]

    Technology appraisal guidance
    Discontinued

  9. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA205)

    This guidance has been updated and replaced by NICE technology appraisal guidance 293.

    Technology appraisal guidance
    Published
    27 October 2010

  10. Research recommendations

    NICE recommends that research should be carried out to directly compare eltrombopag with non-thrombopoietin receptor agonist treatments...